BioMarin Pharma (BMRN) Tops Q2 EPS by 31c, Offers Guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $64.63 -2.86%
EPS Growth %: +1,016.7%
Financial Fact:
Weighted average common shares outstanding, diluted: 167.71M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +1,016.7%
Financial Fact:
Weighted average common shares outstanding, diluted: 167.71M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $0.54, $0.31 better than the analyst estimate of $0.23. Revenue for the quarter came in at $595.3 million versus the consensus estimate of $595.22 million.
GUIDANCE:
BioMarin Pharma sees FY2023 EPS of $1.80-$2.05, versus the consensus of $1.02. BioMarin Pharma sees FY2023 revenue of $2.375-2.5 million, versus the consensus of $2.46 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- Canaan Inc. (CAN) PT Lowered to $2 at BTIG
- Chime to acquire Stride Bank for $590M in cash
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
